FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o Sodium Pyruvate: 1X Liquid

FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o Sodium Pyruvate: 1X Liquid

FluxMPS™ DCP-DMEMLH-P1X is a Microfluidics Suitable, ultra-filtered DMEM Low Glucose + HEPES formulation engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration. This formulation retains sodium bicarbonate (3700 mg/L) as its primary buffer; 25 mM HEPES (pKa 7.3 at 37°C) is included as a supplemental buffer for pH stability during bench manipulations outside the incubator — it does not replace the CO₂ requirement created by the bicarbonate concentration.

• Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final polish for microfluidic channel safety
• Low Glucose (D-Glucose, 1000 mg/L) + L-Glutamine (584 mg/L) + Sodium Bicarbonate (3700 mg/L) + 25 mM HEPES (5958 mg/L); formulated without sodium pyruvate for researcher-defined metabolic supplementation
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>), verified per manufacturing batch
• Ultrapure Type 1 water (18.2 MΩ·cm) and ISO Class 5 aseptic fill & finish
• Manufactured under an ISO 13485:2016 quality management system; final QC at Diagnocine, Totowa, NJ
• Phenol red sodium salt included (15.9 mg/L) for visual pH monitoring — red-colored, clear solution
• Custom pH, glucose, salt, and nutrient adjustments available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma-sized particles, subvisible particulates, and aggregate debris that clog microfluidic channels and corrupt sensor signals. FluxMPS™ addresses these failure modes with a four-stage sub-0.04 µm filtration train. Sodium bicarbonate remains the primary buffer in this formulation; supplemental HEPES improves pH stability outside the incubator.

Quadruple-stage filtration system

Four serial filtration stages, arranged as two dedicated prefilter-plus-final-filter pairs, reach a final 0.04 µm polish under aseptic conditions.

1. 1

   0.1 µm Prefiltration I

   Removes large aggregates, cell debris and protein aggregates; protects the first 0.04 µm final filter cartridge and provides initial mycoplasma-retentive filtration (mycoplasma diameter approximately 0.2–0.3 µm).

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a conventional 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated 0.1 µm prefilter, protecting the second 0.04 µm final filter cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate 0.04 µm polishing filter; aseptic fill and finish under validated ISO Class 5 conditions.

Designed for next-generation cell models

FluxMPS™ DCP-DMEMLH-P1X supports platforms from single-channel microfluidic chips to multi-organ body-on-a-chip systems. Supplemental 25 mM HEPES buffering aids pH stability during bench handling and off-incubator manipulations.

Automated Bioreactors & Robotics

Optional 0.01 µm (10 nm) ultra-filtered MPS Grade variant available on request for automated bioreactor perfusion and robotic liquid handlers — a separate tier from the 0.04 µm Microfluidics Suitable product on this page.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates
• Valve & Sensor Protection: Reduces micro-fouling of solenoid valves and inline optical sensors
• Extended Perfusion Stability: Consistent nutrient delivery over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

33 ingredients verified per lot with CAS numbers for full raw-material traceability.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEMLH-P1X compares

FluxMPS™ DCP-DMEMLH-P1X compared against published supplier specifications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEMLH-P1X.

Supporting literature

Key peer-reviewed publications supporting ultra-filtered, Microfluidics Suitable media in organ-on-a-chip and microfluidic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Ham RG. Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA. 1965;53:288–293. doi:10.1073/pnas.53.2.288
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
6. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
7. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
8. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j